COMMUNIQUÉS West-GlobeNewswire

Tower One Wireless Acquires Mexico Tower Company With AT&T Master Lease Agreement
03/04/2018
VANCOUVER, B.C., April 03, 2018 (GLOBE NEWSWIRE) -- Tower One Wireless Corp (CSE:TO) (OTCQB:TOWTF) (Frankfurt: 1P3N ) (“Tower One” or the “Company”) announces it has signed a definitive agreement further to the [...]
C-RAD signs strategic agreement to equip ZON-PTC, a MAASTRO CLINIC company, in Maastricht, Netherlands for Catalyst PT
03/04/2018
C-RAD announced today that it is entering into a collaboration with the Zuid-Oost Nederland Protonen Therapie Centrum (ZON-PTC) located at and largely owned by MAASTRO clinic, to develop integration of its Catalyst PT [...]
Shire plc : Director Declaration
03/04/2018
Director Declaration April 3, 2018 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the "Company") announces that Sara Mathew, Non-Executive Director of the Company, was appointed Director of State Street Corporation on March 29, [...]
April 3, 2018 is Oncology Nursing Day
03/04/2018
VANCOUVER, British Columbia, April 03, 2018 (GLOBE NEWSWIRE) -- In honour of the 15 th annual Oncology Nursing Day, the Canadian Association of Nurses in Oncology invites you to view its new video that shows how [...]
RavenQuest Signs MOU to Acquire Western AgriPharma Limited
03/04/2018
Vancouver, British Columbia, April 03, 2018 (GLOBE NEWSWIRE) -- RavenQuest BioMed Inc. (the “Company” or “RavenQuest”) – (CSE:RQB)(OTCQB:RVVQF)(Frankfurt: 1IT ) is pleased to announce that it has signed a Memorandum of [...]
Status update of the Phase III ARAMIS clinical trial with darolutamide in patients with non-metastatic castration-resistant prostate cancer
03/04/2018
ORION CORPORATION PRESS RELEASE 3 APRIL 2018 at 10.30 EEST Status update of the Phase III ARAMIS clinical trial with darolutamide in patients with non-metastatic castration-resistant prostate cancer Orion announced [...]
BioPorto receives intention to grant for a divisional NGAL cutoff patent in Europe
03/04/2018
April 3, 2018 Announcement no. 7 BioPorto receives intention to grant for a divisional NGAL cutoff patent in Europe The European Patent Office has published intention to grant BioPorto’s patent no. EP3208616. The patent [...]
Solon Eiendom ASA : Sales in Q1 2018
03/04/2018
Oslo, April 3, 2018 - Solon Eiendom sold 124 homes with a total sales value of NOK 819 million during the first quarter of 2018 compared to 58 homes with a total sales value of NOK 407 million in the first quarter of [...]
Publication of Biohit Oyj Annual Report 2017
03/04/2018
Biohit Oyj Annual Financial Report April 3, 2018 at 9:30 am local time (EET) Biohit Oyj’s Annual Report 2017 is published today in PDF format. The annual report contains financial statements for 2017, the Report of the [...]
Immunicum AB (publ) Provides Update on Ilixadencel Clinical Development Program
03/04/2018
Press Release 3 April 2018 Immunicum AB (publ) Provides Update on Ilixadencel Clinical Development Program Immunicum AB (publ; IMMU.ST) provided today an update on planned, ongoing and previously completed clinical [...]
Shire plc : Rule 2.9 Announcement
03/04/2018
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. 3 April 2018 Shire [...]
genedrive to premier its Genedrive® Hepatitis C test in Asia Pacific
03/04/2018
3 April 2018 genedrive plc ("genedrive" or the "Company") Genedrive® HCV ID Kit to be presented at MEDLAB Asia Pacific Exhibition & Congress genedrive plc (AIM: GDR), the near patient molecular diagnostics company, [...]
Motif Bio Initiates NDA Rolling Submission for Iclaprim and Provides Business Update
03/04/2018
NEW YORK, April 03, 2018 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM:MTFB) (NASDAQ: MTFB ), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced the initiation of a rolling [...]
DBV Technologies to Attend the 11th Kempen Life Sciences Conference
03/04/2018
Montrouge, April 3, 2018 DBV Technologies to Attend the 11 th Kempen Life Sciences Conference DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT) today announced that Susanna Mesa, Chief [...]
DBV Technologies invitée à participer à la 11ème Life Sciences Conference de Kempen
03/04/2018
Montrouge, France, le 3 avril, 2018 (7H30 CEST) DBV Technologies invitée à participer à la 11ème Life Sciences Conference de Kempen DBV Technologies (Euronext : DBV - ISIN : FR0010417345 - Nasdaq : DBVT), une société [...]
Sanofi: EMA to review cemiplimab as a potential treatment for advanced cutaneous squamous cell carcinoma
03/04/2018
Press Release Source: Sanofi (EURONEXT: SAN) (NYSE: SNY) EMA to review cemiplimab as a potential treatment for advanced cutaneous squamous cell carcinoma Paris and Tarrytown, NY - April 3, 2018 - The European Medicines [...]
Sanofi : L'EMA va examiner le cemiplimab comme traitement potentiel du carcinome épidermoïde cutané au stade avancé
03/04/2018
Communiqué de presse Source : Sanofi (EURONEXT : SAN) (NYSE : SNY) L'EMA va examiner le cemiplimab comme traitement potentiel du carcinome épidermoïde cutané au stade avancé Paris et Tarrytown (New York) - Le 3 avril [...]
Sanofi: EMA to review Dupixent® (dupilumab) as potential treatment for inadequately controlled moderate-to-severe asthma
03/04/2018
Press Release Source: Sanofi (EURONEXT: SAN) (NYSE: SNY) EMA to review Dupixent ® (dupilumab) as potential treatment for inadequately controlled moderate-to-severe asthma Paris and Tarrytown, NY - April 3, 2018 - The [...]
Sanofi : L'EMA va examiner Dupixent® (dupilumab) dans le traitement potentiel de l'asthme modéré à sévère inadéquatement contrôlé
03/04/2018
Communiqué de presse Source : Sanofi (EURONEXT : SAN) (NYSE : SNY) L'EMA va examiner Dupixent® (dupilumab) dans le traitement potentiel de l'asthme modéré à sévère inadéquatement contrôlé Paris et Tarrytown (New York [...]

Pages